Sedative-Hypnotic Drugs for the Treatment of Primary Chronic Insomnia Disorder

Sedative-hypnotic drugs are used to reduce tension and anxiety and to induce calm (sedative effect) or sleep (hypnotic effect). Following clinical guidelines and product information, these drugs should not be prescribed for longer than four weeks for primary chronic insomnia disorder. The current total costs of these drugs have a large impact on the national healthcare budget. Despite the high costs, potential harms and clear discouraging guideline recommendations for long-term sedative-hypnotic drug treatment, the rates of sedative-hypnotic drugs use have not changed meaningfully over time.

The aim of this HTA is to investigate the clinical efficacy, effectiveness, safety, and cost-effectiveness of intermediate (1-6 months) and long-term (≥6 months) use of sedative-hypnotic drugs of ATC categories N05BA (benzodiazepine derivatives), N05CD (benzodiazepine derivatives), or N05CF (Z-drugs/benzodiazepine related drugs) listed in the Swiss speciality list to treat primary chronic insomnia disorder compared to placebo, no treatment, or other non-pharmacological treatment, or compared to the short-term use (≤ one month) of sedative-hypnotic drugs.

Last modification 09.02.2022

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/sedativa.html